<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558259</url>
  </required_header>
  <id_info>
    <org_study_id>1160.63</org_study_id>
    <secondary_id>2007-002586-12</secondary_id>
    <nct_id>NCT00558259</nct_id>
  </id_info>
  <brief_title>Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE</brief_title>
  <acronym>RE-SONATE</acronym>
  <official_title>Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to
      placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in
      patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed
      6 to 18 months of treatment with vitamin K antagonist (VKA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally Confirmed Unexplained Deaths During the Intended Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally Confirmed Bleeding Event During the Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:
Fatal bleeding
Associated with a fall in haemoglobin of ≥2 g/dL
Led to the transfusion of ≥2 units packed cells or whole blood
Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal
Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.
Examples of these bleedings were:
Bleeding that compromised haemodynamics
Bleeding that led to hospitalisation
Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.
All bleeding events include MBEs, CRBEs, and trivial bleeding events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally Confirmed Cardiovascular Events During the Treatment Period</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures, Especially Liver Function Tests (LFTs)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with possible clinically significant abnormalities during the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1353</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate 150 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive dabigatran etexilatate capsules 150 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo twice daily (BID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient to receive dabigatran extexilate matching placebo capsules twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate 150 mg twice daily (BID)</intervention_name>
    <description>dabigatran etexilate capsules 150 mg BID</description>
    <arm_group_label>dabigatran etexilate 150 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo twice daily (BID)</intervention_name>
    <description>Matching placebo BID</description>
    <arm_group_label>matching placebo twice daily (BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with confirmed symptomatic PE or proximal DVT of the leg(s) who have been
             treated for 6 to 18 months with therapeutic dosages (intended INR between 2-3) of an
             oral VKA (e.g. warfarin, acenocoumarol, phenprocoumon, or fluindione) or RE-COVER
             study medication up to the moment of screening for the current study.

          2. Written informed consent

        Exclusion criteria:

          1. Younger then 18 years of age

          2. Indication for VKA other than DVT and/or PE

          3. Patients in whom anticoagulant treatment for their index PE or DVT should be continued

          4. Active liver disease or liver disease decreasing survival (e.g. acute hepatitis,
             chronic active hepatitis, cirrhosis) or ALAT &gt; 3 x ULN

          5. Creatinine clearance &lt; 30 ml/min

          6. Acute bacterial endocarditis

          7. Active bleeding or high risk for bleeding.

          8. Uncontrolled hypertension (investigators judgement)

          9. Intake of another experimental drug within the 30 days prior to randomization into the
             study

         10. Life expectancy &lt;6 months

         11. Childbearing potential without proper contraceptive measures*, pregnancy or breast
             feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.63.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Key West</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Iberia</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duffel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lier</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.02013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.02004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.02020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kladno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nymburk</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 4-Krc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prostejov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rakovnik</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.42014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kohtla-Järve</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Püttlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Castelfranco Veneto (TV)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chieti Scalo (CH)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fidenza (PR)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.39016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vittorio veneto (TV)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyunggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Helder</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dirksland</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oss</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.48008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.07014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.65001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.27009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Värnamo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruderholz</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cham</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glarus</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Luzern 16</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schiers</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thun</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wetzikon</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zug</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.41006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.66002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.66003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.66004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.63.66001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Norway</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <results_first_submitted>January 31, 2012</results_first_submitted>
  <results_first_submitted_qc>January 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2012</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 3 patients randomised to placebo who received Dabigatran only. For all analyses of efficacy, these patients are analysed as randomised. For all analyses of safety, these patients are analysed as treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran</title>
          <description>Dabigatran 150mg bid (twice daily)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="681">Number who started treatment. There were 4 patients randomised to Dabigatran and not treated.</participants>
                <participants group_id="P2" count="662">Number who started treatment. There were 6 patients randomised to placebo and not treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="610">Completed treatment.</participants>
                <participants group_id="P2" count="563">Completed treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran</title>
          <description>Dabigatran 150mg bid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="681"/>
            <count group_id="B2" value="662"/>
            <count group_id="B3" value="1343"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="15.5"/>
                    <measurement group_id="B2" value="55.5" spread="15.1"/>
                    <measurement group_id="B3" value="55.8" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="298"/>
                    <measurement group_id="B3" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="381"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI) continuous</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.45" spread="5.44"/>
                    <measurement group_id="B2" value="28.41" spread="5.56"/>
                    <measurement group_id="B3" value="28.43" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period</title>
        <description>Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.</description>
        <time_frame>6 months</time_frame>
        <population>Full analysis set (FAS) and analysed as randomised. FAS is defined as randomised and treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period</title>
          <description>Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.</description>
          <population>Full analysis set (FAS) and analysed as randomised. FAS is defined as randomised and treated.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.0"/>
                    <measurement group_id="O2" value="37" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period</title>
        <description>Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.</description>
        <time_frame>6 months</time_frame>
        <population>FAS and analysed as randomised.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Excluding Unexplained Death During the Intended Treatment Period</title>
          <description>Symptomatic recurrent VTE is the composite of recurrent deep vein thrombosis (DVT) , fatal or non-fatal pulmonary embolism (PE). Whilst the endpoint is time to event, the measured values present the number of participant with event and the hazard ratio presents the time to event.</description>
          <population>FAS and analysed as randomised.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period</title>
        <description>Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described.</description>
        <time_frame>6 months</time_frame>
        <population>FAS and analysed as randomised.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Centrally Confirmed Symptomatic Recurrent Deep Venous Thrombotic (DVT) Events During the Intended Treatment Period</title>
          <description>Number of the participants with centrally confirmed symptomatic recurrent deep venous thrombotic (DVT) events during the intended treatment period were described.</description>
          <population>FAS and analysed as randomised.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants experiencing DVT in Dabigatran group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.21</ci_lower_limit>
            <ci_upper_limit>5.17</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants experiencing DVT in placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period</title>
        <description>Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described.</description>
        <time_frame>6 months</time_frame>
        <population>FAS and analysed as randomised.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period</title>
          <description>Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described.</description>
          <population>FAS and analysed as randomised.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants experiencing PE in Dabigatran group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>3.52</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants experiencing PE in placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Centrally Confirmed Unexplained Deaths During the Intended Treatment Period</title>
        <description>Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described.</description>
        <time_frame>6 months</time_frame>
        <population>FAS and analysed as randomised.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Centrally Confirmed Unexplained Deaths During the Intended Treatment Period</title>
          <description>Number of participants with centrally confirmed unexplained deaths during the intended treatment period were described.</description>
          <population>FAS and analysed as randomised.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="681"/>
                <count group_id="O2" value="662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2428</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants with unexplained death in Dabigatran group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants with unexplained death in placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Centrally Confirmed Bleeding Event During the Treatment Period</title>
        <description>Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:
Fatal bleeding
Associated with a fall in haemoglobin of ≥2 g/dL
Led to the transfusion of ≥2 units packed cells or whole blood
Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal
Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.
Examples of these bleedings were:
Bleeding that compromised haemodynamics
Bleeding that led to hospitalisation
Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.
All bleeding events include MBEs, CRBEs, and trivial bleeding events.</description>
        <time_frame>6 months</time_frame>
        <population>FAS and analysed as treated. There were 3 participants who were randomised to placebo but treated with dabigatran only.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Centrally Confirmed Bleeding Event During the Treatment Period</title>
          <description>Major bleeding events (MBE) had to fulfil at least 1 of the following criteria:
Fatal bleeding
Associated with a fall in haemoglobin of ≥2 g/dL
Led to the transfusion of ≥2 units packed cells or whole blood
Occurred in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal
Other clinically relevant bleeding was defined as overt bleeding not meeting the criteria for an MBE but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.
Examples of these bleedings were:
Bleeding that compromised haemodynamics
Bleeding that led to hospitalisation
Trivial bleeding events were defined as all other bleeding events that did not fulfil the criteria of MBEs or CRBEs.
All bleeding events include MBEs, CRBEs, and trivial bleeding events.</description>
          <population>FAS and analysed as treated. There were 3 participants who were randomised to placebo but treated with dabigatran only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="684"/>
                <count group_id="O2" value="659"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MBE or CRBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Placebo - Analysis of time to first occurrence of an MBE during the treatment period - FAS - as treated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4998</p_value>
            <p_value_desc>As the Cox model did not converge due to too few events, hazard ratios are not estimable.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants experiencing MBE in Dabigatran group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants with events</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
            <estimate_desc>The confidence interval (Clopper-Pearson method) was calculated for the percentage of participants experiencing MBE in placebo group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Placebo- Analysis of time to first occurrence of a MBE or CRBE during the treatment period - FAS - as treated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>5.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Placebo- Analysis of time to first occurrence of any bleeding event during the treatment period - FAS - as treated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Centrally Confirmed Cardiovascular Events During the Treatment Period</title>
        <description>Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups.</description>
        <time_frame>6 months</time_frame>
        <population>FAS and analysed as treated. There were 3 participants who were randomised to placebo but treated with dabigatran only.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Centrally Confirmed Cardiovascular Events During the Treatment Period</title>
          <description>Cardiovascular events that occurred during the treatment period + 3 days were summarised by treatment groups.</description>
          <population>FAS and analysed as treated. There were 3 participants who were randomised to placebo but treated with dabigatran only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="684"/>
                <count group_id="O2" value="659"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures, Especially Liver Function Tests (LFTs)</title>
        <description>Number of participants with possible clinically significant abnormalities during the treatment period.</description>
        <time_frame>6 months</time_frame>
        <population>FAS − As Treated Assignment</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures, Especially Liver Function Tests (LFTs)</title>
          <description>Number of participants with possible clinically significant abnormalities during the treatment period.</description>
          <population>FAS − As Treated Assignment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="684"/>
                <count group_id="O2" value="659"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST increase (N=655, 629)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase (N=655, 629)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase increase (N=658, 629)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin increase (N=658, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>There were 3 patients who were randomised to placebo but who were treated with dabigatran only.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran</title>
          <description>Dabigatran 150mg bid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Arthrofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="659"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

